Spatial Genomics Identifies Heat Shock Proteins As Key Molecular Changes Associated to Adipose Periprostatic Space Invasion in Prostate Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Date 2025 Jan 11

PMID 39796635

Authors

Olivier Cussenot

Lucie Poupel

Coralie Mousset

Julien Lavergne

Franck Bruyere

Alix Fontaine

Geraldine Cancel-Tassin

Gaelle Fromont-Hankard

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify molecular changes during PCa invasion of adipose space using Spatial Transcriptomic Profiling of PCa cells.

Methods: This study was performed on paired intraprostatic and extraprostatic samples obtained from radical prostatectomy with pT3a pathological stages.

Results: Differential gene expression revealed upregulation of heat shock protein genes: DNAJB1, HSPA8, HSP90AA1, HSPA1B, HSPA1A in PCa PanCK+ cells from the adipose periprostatic space. Extraprostatic extension was significantly associated with overexpression of genes involved in metastatic spread (EGR1, OR51E2, SPON2), of aggressiveness ERG negative signature of enhancers of androgen receptor (HOXB13, FOXA1), and of PSMA (FOLH1). They were associated with loss at 6q, 10q, 16q, and gain at 8q24 locus.

Conclusions: PCa invasion of adipose EPE induces adaptative process related to heat shock proteins; PCa cells in EPE also present transcriptomics signatures for ERG independent aggressiveness, androgen receptor co-activation, and specific CNV changes.

References

Cancel M, Pouillot W, Maheo K, Fontaine A, Crottes D, Fromont G . Interplay between Prostate Cancer and Adipose Microenvironment: A Complex and Flexible Scenario. Int J Mol Sci. 2022; 23(18). PMC: 9500873. DOI: 10.3390/ijms231810762. View

Hankey W, Chen Z, Wang Q . Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors. Cancer Res. 2020; 80(12):2427-2436. PMC: 7299826. DOI: 10.1158/0008-5472.CAN-19-3447. View

Abe M, Manola J, Oh W, Parslow D, George D, Austin C . Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer. 2004; 3(1):49-53. DOI: 10.3816/cgc.2004.n.013. View

Li L, Ameri A, Wang S, Jansson K, Casey O, Yang Q . EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 2019; 38(35):6241-6255. PMC: 6715537. DOI: 10.1038/s41388-019-0873-8. View

Fourquet A, Lahmi L, Rusu T, Belkacemi Y, Crehange G, De La Taille A . Restaging the Biochemical Recurrence of Prostate Cancer with [Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management. Cancers (Basel). 2021; 13(7). PMC: 8038030. DOI: 10.3390/cancers13071594. View

Woodcock D, Sahli A, Teslo R, Bhandari V, Gruber A, Ziubroniewicz A . Genomic evolution shapes prostate cancer disease type. Cell Genom. 2024; 4(3):100511. PMC: 10943594. DOI: 10.1016/j.xgen.2024.100511. View

Dai Y, Chen P, Lee D, Andrade G, Vallis K . A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer. Eur Urol. 2024; . DOI: 10.1016/j.eururo.2024.09.020. View

Epstein J, Amin M, Boccon-Gibod L, Egevad L, Humphrey P, Mikuz G . Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005; (216):34-63. DOI: 10.1080/03008880510030932. View

Pomerantz M, Li F, Takeda D, Lenci R, Chonkar A, Chabot M . The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015; 47(11):1346-51. PMC: 4707683. DOI: 10.1038/ng.3419. View

10.

Shao X, Lv N, Liao J, Long J, Xue R, Ai N . Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Med Genet. 2019; 20(1):175. PMC: 6842483. DOI: 10.1186/s12881-019-0909-5. View

11.

Xu X, Khater M, Wu G . The olfactory receptor OR51E2 activates ERK1/2 through the Golgi-localized Gβγ-PI3Kγ-ARF1 pathway in prostate cancer cells. Front Pharmacol. 2022; 13:1009380. PMC: 9606680. DOI: 10.3389/fphar.2022.1009380. View

12.

Silva K, Tambwe N, Mahfouz D, Wium M, Cacciatore S, Paccez J . Transcription Factors in Prostate Cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches. Genes (Basel). 2024; 15(4). PMC: 11050257. DOI: 10.3390/genes15040450. View

13.

Ribeiro R, Monteiro C, Cunha V, Azevedo A, Oliveira M, Monteiro R . Tumor cell-educated periprostatic adipose tissue acquires an aggressive cancer-promoting secretory profile. Cell Physiol Biochem. 2012; 29(1-2):233-40. DOI: 10.1159/000337604. View

14.

Teng Y, Ngoka L, Mei Y, Lesoon L, Cowell J . HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. J Biol Chem. 2012; 287(13):10051-10059. PMC: 3323057. DOI: 10.1074/jbc.M111.335000. View

15.

Herroon M, Mecca S, Haimbaugh A, Garmo L, Rajagurubandara E, Todi S . Adipocyte-driven unfolded protein response is a shared transcriptomic signature of metastatic prostate carcinoma cells. Biochim Biophys Acta Mol Cell Res. 2021; 1868(11):119101. PMC: 8475945. DOI: 10.1016/j.bbamcr.2021.119101. View

16.

Zhang J, Liu G, Liu Y, Yang P, Xie J, Wei X . The biological functions and related signaling pathways of SPON2. Front Oncol. 2024; 13:1323744. PMC: 10803442. DOI: 10.3389/fonc.2023.1323744. View

17.

Fu X, Liu J, Yan X, DiSanto M, Zhang X . Heat Shock Protein 70 and 90 Family in Prostate Cancer. Life (Basel). 2022; 12(10). PMC: 9605364. DOI: 10.3390/life12101489. View

18.

Bakht M, Yamada Y, Ku S, Venkadakrishnan V, Korsen J, Kalidindi T . Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023; 4(5):699-715. PMC: 10867901. DOI: 10.1038/s43018-023-00539-6. View

19.

Jillson L, Rider L, Rodrigues L, Romero L, Karimpour-Fard A, Nieto C . Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of . Mol Cancer Res. 2021; 19(7):1123-1136. PMC: 8254790. DOI: 10.1158/1541-7786.MCR-20-0913. View

20.

Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M . Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018; 29(8):1814-1821. DOI: 10.1093/annonc/mdy224. View